Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

References

• Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787–97
   PubMed Web of Science ®Google Scholar
• Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(Suppl 4):S397–S403
   PubMedGoogle Scholar
• Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci 2000;25:137–53
   PubMed Web of Science ®Google Scholar
• Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50:912–24
   PubMed Web of Science ®Google Scholar
• Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W. Amisulpride study group. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999;88:107–17
   Google Scholar
• Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17:383–9
   Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371–6
   Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839–54
   Google Scholar
• Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002;14:123–9
   PubMedGoogle Scholar
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–96
   Google Scholar
• Tandon R, Halbreich U. The second-generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology 2003;28(Suppl 1):1–7
   PubMedGoogle Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998;59(Suppl 12):3–9
   Google Scholar
• Cheer SM, Wagstaff AJ. Quetiapine : a review of its use in the management of schizophrenia. CNS Drugs 2004;18:173–99
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group. J Clin Psychopharmacol 1996;16: 158–69
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549–57
   PubMedGoogle Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 study group. Biol Psychiatry 1997;42:233–46
   Google Scholar
• Fabre Jr. LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17: 366–78
   Google Scholar
• Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665–77
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30: 95–105
   Google Scholar
• Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265–73
   PubMed Web of Science ®Google Scholar
• Tandon R, Mullen J, Sweitzer D. NR242: quetiapine and risperidone in outpatients with schizophrenia: subanalysis of the QUEST trial. American Psychiatric Association Annual Meeting, New Orleans, Louisiana, USA, 5–10 May 2001
   Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121–31
   PubMed Web of Science ®Google Scholar
• Zhong X, Sweitzer D, Russo J, Potter L, Mullen J. A comparison of the efficacy and safety of quetiapine and risperidone. Eur Neuropsychopharmacol 2003;13:S340
   Google Scholar
• Reznik I, Slavkin L, Shabash E, Kertzman S, Shaked G, Spivak B, Weizman A, Kotler M. Quetiapine in recently relapsed patients with schizophrenia: an open-label head-to-head comparative study versus olanzapine. 12th Congress of the Association of European Psychiatrists 2004
   Google Scholar
• Eli Lilly and Company. Olanzapine US Prescribing Information. 2003
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51–68
   Google Scholar
• Srisurapanont M, Maneeton N. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. J Med Assoc Thai 1999;82:341–6
   PubMedGoogle Scholar
• Adams C, Duggan L. Paper corrupts concept of evidence based medicine [letter]. BMJ 2001;322:927–8
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553–64
   PubMed Web of Science ®Google Scholar
• Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol 2001;11:289–93
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757–71
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990–9
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Iskander A, Park M, Apergi F-S, Czobor P, Smith R, Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998;59:521–7
   Google Scholar
• Buckley PF. Broad therapeutic profile of atypical antipsychotics. Biol Psychiatry 2001;50:912–4
   PubMed Web of Science ®Google Scholar